🔎 Trials Near Me

Home › Eye Care › California

Eye Care clinical trials in California

7 studies for Eye Care are looking for participants at sites in California.

Cities in California

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

  • Adverum Clinical Site 109, Bakersfield
  • Adverum Clinical Site 100, Beverly Hills
  • Adverum Clinical Site 201, Campbell
  • and 10 more
RecruitingPhase 3
Ages 50 and older · All sexes · Updated Sep 24, 2026 · NCT07482176

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

  • Adverum site 109, Bakersfield
  • Adverum site 169, Fullerton
RecruitingPhase 2
Ages 50 and older · All sexes · Updated Aug 5, 2026 · NCT07630649

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

  • University of California, San Francisco, San Francisco
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07434635

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

  • UCSF Wayne and Gladys Valley Center for Vision, San Francisco
RecruitingPhase 3
Ages 6 and older · All sexes · Updated Jun 25, 2026 · NCT06891443

Strategies for Improving Linkage-to-Care After Eye Disease Screening

  • University of California, San Francisco, San Francisco
Recruiting
Ages 60 and older · All sexes · Updated Apr 29, 2026 · NCT06943599

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

  • Baxis Site 19, La Jolla
  • Baxis Site 39, Long Beach
  • Baxis Site 31, Los Angeles
  • and 1 more
RecruitingPhase 3
All ages · All sexes · Updated Mar 17, 2026 · NCT06911424

IRIS Registry: Intelligent Research in Sight Registry

  • American Academy of Opthalmology, San Francisco
RecruitingObservational study
6 Months · All sexes · Updated Jul 12, 2016 · NCT02485847

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.